Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.

Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent

Fixed dose of LABA as prescribed prior to study entry

Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.